{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:10:12Z","timestamp":1756321812704,"version":"3.44.0"},"reference-count":24,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,6,5]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Atezolizumab is an immune checkpoint inhibitor that targets PDL-1 (programmed death ligand-1) on the tumour cells and inactivates it. The addition of this drug to chemotherapy has led to survival benefits in the treatment of small cell lung cancer-extensive stage (SCLC-ES). However, these excellent outcomes may be marred by the development of immune-mediated adverse events (irAEs). The pathophysiology of these irAEs is not well defined, and as a result, they are less understood as an entity. In addition to this, the highly non-specific presentation and unawareness among treating physicians may lead to delays in diagnosis and subsequently affect patient outcomes. Immunotherapy-induced myositis is one such rare irAE.<\/jats:p>\n               <jats:p>Herein, we present a case of a male in his early 70\u2009s undergoing treatment for SCLC-ES, who initially presented with non-specific symptoms and grade four transaminitis and was subsequently diagnosed with atezolizumab-related myositis after comprehensive evaluation. The patient was managed successfully and has an ongoing response more than 6\u2009months after stopping immunotherapy and 18 months since initial diagnosis. This case report aims to address the knowledge gap regarding this irAE with insights on diagnosis and management.<\/jats:p>","DOI":"10.1136\/bcr-2025-264962","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T04:10:28Z","timestamp":1750133428000},"page":"e264962","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical insights: atezolizumab-induced myositis mimicking hepatic injury"],"prefix":"10.1136","volume":"18","author":[{"given":"Bhumi","family":"Agarwal","sequence":"first","affiliation":[{"name":"Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-9824","authenticated-orcid":false,"given":"Ullas","family":"Batra","sequence":"additional","affiliation":[{"name":"Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritwika","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Rheumatology, King George\u2019s Medical University, Lucknow, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"2025082711323971000_18.6.e264962.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2025082711323971000_18.6.e264962.2","doi-asserted-by":"crossref","first-page":"107924","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer (Auckl)"},{"key":"2025082711323971000_18.6.e264962.3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"2025082711323971000_18.6.e264962.4","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000597"},{"key":"2025082711323971000_18.6.e264962.5","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-236357","article-title":"Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma","volume":"13","author":"Sessums","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2025082711323971000_18.6.e264962.6","unstructured":"National Cancer Institute . Common terminology criteria for adverse events (CTCAE) v5.0. CancerGov: Bethesda, MD; 2017. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"2025082711323971000_18.6.e264962.7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025082711323971000_18.6.e264962.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2025082711323971000_18.6.e264962.9","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.3390\/ijms21093054","article-title":"Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"IJMS"},{"key":"2025082711323971000_18.6.e264962.10","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025082711323971000_18.6.e264962.11","doi-asserted-by":"crossref","first-page":"803410","DOI":"10.3389\/fimmu.2021.803410","article-title":"Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis","volume":"12","author":"Hamada","year":"2021","journal-title":"Front Immunol"},{"key":"2025082711323971000_18.6.e264962.12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","article-title":"Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis","volume":"24","author":"Xu","year":"2019","journal-title":"Neurologist"},{"key":"2025082711323971000_18.6.e264962.13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286"},{"key":"2025082711323971000_18.6.e264962.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226"},{"key":"2025082711323971000_18.6.e264962.15","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/art.41604","article-title":"Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025082711323971000_18.6.e264962.16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/10781552231203190","article-title":"Atezolizumab-induced myositis in a patient with small-cell lung cancer","volume":"30","author":"Sahin","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"2025082711323971000_18.6.e264962.17","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.3390\/jcm11195611","article-title":"Immune Checkpoint Inhibitor-Induced Myositis\/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit","volume":"11","author":"Deharo","year":"2022","journal-title":"J Clin Med"},{"key":"2025082711323971000_18.6.e264962.18","doi-asserted-by":"crossref","first-page":"5399073","DOI":"10.1155\/2024\/5399073","article-title":"Immunotherapy-Induced Overlap Syndrome: Myositis, Myasthenia Gravis, and Myocarditis-A Case Series","volume":"2024","author":"Aggarwal","year":"2024","journal-title":"Case Rep Med"},{"key":"2025082711323971000_18.6.e264962.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2025082711323971000_18.6.e264962.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"2025082711323971000_18.6.e264962.21","doi-asserted-by":"crossref","first-page":"5126717","DOI":"10.1155\/2020\/5126717","article-title":"The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma","volume":"2020","author":"Jeyakumar","year":"2020","journal-title":"Case Reports Immunol"},{"key":"2025082711323971000_18.6.e264962.22","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025082711323971000_18.6.e264962.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257"},{"key":"2025082711323971000_18.6.e264962.24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-264962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:32:50Z","timestamp":1756319570000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-264962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bcr-2025-264962"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-264962","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}